07/ 10/ 2026
Bestcomm Ranked in Top 50 Pharmaceutical R&D Companies In China
Bestcomm won "Independent Innovation Enterprise" and "Top 50 R&D Company" at the 2025–2026 Industry Conference.
07/ 03/ 2026
ICH Releases E6(R3) Annex 2: Clinical Trial Quality Management Enters the Era of "Decentralised + Real-World Data"
ICH E6(R3) Annex 2 provides GCP guidance for decentralised, pragmatic, and RWD‑enriched trials. It emphasises proportionality, QbD, patient engagement, and early regulator dialogue, reshaping clinical trial quality management for the digital era.
06/ 26/ 2026
Bestcomm Pharmaceutical Selected in 2026 China Top 20 Pharmaceutical CRO Enterprises
Bestcomm Pharmaceutical has been named among the 2026 Top 20 Chinese Pharmaceutical CRO Enterprises by the PDI Summit. The ranking evaluates revenue, R&D investment, headcount, brand awareness, and more. As a leading one‑stop R&D solution provider, Bestcomm is committed to accelerating innovative drug development and delivering high‑quality therapies to patients.
